These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6847139)

  • 41. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
    Sánchez-Chapado M; Angulo Cuesta J; Guil Cid M; Jiménez FJ; López Alvarez YJ
    Arch Esp Urol; 1995 Dec; 48(10):979-83. PubMed ID: 8588730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of parkinsonism with dopaminergic system agonists].
    Dowzenko A
    Neurol Neurochir Pol; 1976; 10(4):579-82. PubMed ID: 958587
    [No Abstract]   [Full Text] [Related]  

  • 44. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients.
    Kuno S; Mizuta E; Yamasaki S; Araki I
    Parkinsonism Relat Disord; 2004 Mar; 10(3):181-7. PubMed ID: 15036175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
    Factor SA; Sanchez-Ramos JR; Weiner WJ
    J Neurol Neurosurg Psychiatry; 1988 Apr; 51(4):529-33. PubMed ID: 3288717
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical studies with bromocriptine in idiopathic parkinsonism.
    Teychenne PF; Kartzinel R; Perlow M; Pfeiffer R; Calne DB
    Trans Am Neurol Assoc; 1976; 101():302-4. PubMed ID: 1037483
    [No Abstract]   [Full Text] [Related]  

  • 48. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
    Serby M; Angrist B; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908
    [No Abstract]   [Full Text] [Related]  

  • 49. Amantadine-induced myoclonus in a patient with progressive supranuclear palsy.
    Yarnall AJ; Burn DJ
    Age Ageing; 2012 Sep; 41(5):695-6. PubMed ID: 22421702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of progressive supranuclear palsy with tricyclic antidepressants.
    Newman GC
    Neurology; 1985 Aug; 35(8):1189-93. PubMed ID: 3895032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases.
    Mastaglia FL; Grainger K; Kee F; Sadka M; Lefroy R
    Proc Aust Assoc Neurol; 1973; 10(0):35-44. PubMed ID: 4792160
    [No Abstract]   [Full Text] [Related]  

  • 52. Progressive supranuclear palsy (report of 4 cases with particular reference to blepharospasm and levodopa therapy).
    Singh S; Smith BH; Lal A
    Neurol India; 1974 Jun; 22(2):65-71. PubMed ID: 4437701
    [No Abstract]   [Full Text] [Related]  

  • 53. An atypical case of progressive supranuclear palsy.
    Gomori AJ; Sima AA
    Can J Neurol Sci; 1984 Feb; 11(1):48-52. PubMed ID: 6322950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Progressive supranuclear palsy. Diagnostic problems].
    Kristensen MO
    Ugeskr Laeger; 1985 Sep; 147(39):3074-5. PubMed ID: 4071761
    [No Abstract]   [Full Text] [Related]  

  • 55. [Progressive supranuclear palsy: a case report and etiological study of eye movement disturbance].
    Kawamura Y; Shibazaki H; Shida K; Goto I; Kuroiwa Y
    Rinsho Shinkeigaku; 1975 Aug; 15(8):535-40. PubMed ID: 1237380
    [No Abstract]   [Full Text] [Related]  

  • 56. Progress in the pharmacotherapy of Parkinsonism.
    Calne DB; Eisler T; Gopinathan G; Williams A
    Adv Biochem Psychopharmacol; 1980; 23():237-43. PubMed ID: 6104907
    [No Abstract]   [Full Text] [Related]  

  • 57. Dopamine agonists in hyperprolactinemia.
    Mattox JH
    Fertil Steril; 1985 Oct; 44(4):555-7. PubMed ID: 4054333
    [No Abstract]   [Full Text] [Related]  

  • 58. [Bulbar palsy, Parkinsonism and dementia--a case report].
    Ishii N; Nishimaru K; Okumura M; Kikuchi M
    Rinsho Shinkeigaku; 1976 Jul; 16(7):483-90. PubMed ID: 986918
    [No Abstract]   [Full Text] [Related]  

  • 59. Letter: Bromocriptine in parkinsonism.
    Lees AJ; Shaw KM; Stern GM
    Lancet; 1975 Oct; 2(7937):709-10. PubMed ID: 52084
    [No Abstract]   [Full Text] [Related]  

  • 60. [Endocrine effects of bromocryptin in patients with Parkinsonism].
    Barreca T; Gianrossi R; Gallamini A; Nizzo MC; Queirolo A
    Boll Soc Ital Biol Sper; 1976 Oct; 52(19):1564-7. PubMed ID: 1037379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.